Sumary of FDA clears IND application for ‘controllable’ CAR-T to treat advanced multiple myeloma:
- The FDA cleared an investigational new drug application for ACLX-001, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma, according to the agent manufacturer..
- ACLX-001 (Arcellx) is an autologous, gene-edited CAR T-cell therapy with a novel binding domain that targets the B-cell maturation antigen (BCMA) on the surface of cancer cells..
- The investigational therapy binding domain was developed using Arcellx proprietary platform, in which antigen receptor complex T cells (ARC-T) are controlled by a tumor-targeting protein called a SparX (soluble protein antigen-receptor X-linker)..
- “ARC-T cells cannot recognize the tumor without SparX proteins and can only destroy a diseased cell when attached to a SparX-antigen complex,”.
- Data presented at last year virtual ASH Annual Meeting showed all six patients responded to therapy, with four achieving complete stringent response..
- “Demonstrating a safe and effective cell therapy that is controllable and adaptable has the potential to be transformative for the field of cell and gene therapy,”…